Streetbeat News

KVUE

Kenvue Inc.

https://www.kenvue.com

Industry

Household & Personal Products

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.

Open

22.87

Mkt cap

45B

Volume

17M

High

23.72

P/E Ratio

43.05

52-wk high

23.72

Low

22.85

Div yield

0.03

52-wk low

17.67

Pfizer, AstraZeneca, Sanofi, and other pharmaceutical companies are investing heavily in France to expand their operations. Pfizer and AstraZeneca will invest nearly $1 billion combined, while Sanofi will invest $1.1 billion. Other companies like AbbVie, Novartis, and Kenvue are also increasing their presence in France. Additionally, Mainz Biomed is expected to unveil breakthrough early cancer detection results in the US.

Portfolio Pulse from Upwallstreet

May 16, 2024 | 12:51 pm

Kenvue has priced a secondary offering of 182.3 million shares of common stock at $20 per share.

Portfolio Pulse from Charles Gross

May 14, 2024 | 11:17 pm

Kenvue shares are trading lower following the announcement of a secondary offering by selling shareholders.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:15 am

Kenvue Inc. announced a secondary offering of 182.3 million shares by selling stockholders, with no proceeds going to Kenvue. Johnson & Johnson will exchange its Kenvue shares for indebtedness held by Goldman Sachs & Co. LLC and J.P. Morgan, who will then sell the shares in the offering. Post-offering, Johnson & Johnson will not own any Kenvue shares.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 10:48 am

Kenvue has filed for an offering of 182.3 million shares of common stock by selling shareholders, as detailed in their S-1 filing.

Portfolio Pulse from Charles Gross

May 13, 2024 | 10:43 am

Analyst ratings for Kenvue (NYSE:KVUE) show varied perspectives, with recent evaluations ranging from bullish to bearish. The average 12-month price target is now $21.57, down from $23.20. Analyst actions include adjustments to ratings and price targets, reflecting changes in market conditions and company performance. Kenvue, a spin-off from Johnson & Johnson's consumer segment, is the world's largest pure-play consumer health company, facing a slight revenue decline but maintaining strong profitability indicators.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 6:01 pm

HSBC analyst Jeremy Fialko has maintained a Hold rating on Kenvue (NYSE:KVUE) and increased the price target from $20 to $21.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 5:50 pm

US stocks are on track for a fourth consecutive session of gains despite hawkish comments from Fed's Kashkari, with the S&P 500, Nasdaq 100, and Dow Jones all seeing modest increases. Treasury yields fell, boosting bond ETFs like TLT. Palantir and Disney shares tumbled following disappointing guidance and performance, respectively. Other notable stock movements were influenced by earnings reports and rumors of partnerships.

Portfolio Pulse from Piero Cingari

May 07, 2024 | 5:18 pm

Kenvue Inc (NYSE:KVUE), a consumer health company, reported Q1 sales of $3.89 billion, surpassing expectations of $3.79 billion. Sales grew by 1.1%, with organic growth at 1.9%. The company saw increases in Self Care and Essential Health segments but faced a decline in Skin Health and Beauty. Adjusted EPS was $0.28, beating the consensus of $0.26. Kenvue plans to cut its workforce by 4% aiming for $350 million in cost savings by 2026, expecting to incur $275 million in restructuring costs over the next two years. The company anticipates 1.0%-3.0% net sales growth and an adjusted EPS of $1.10-$1.20 for FY 2024. KVUE shares rose 4.95% to $20.03.

Portfolio Pulse from Vandana Singh

May 07, 2024 | 4:52 pm

Kenvue shares have experienced an increase in their trading value after the company reported financial results for the first quarter that surpassed expectations.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:57 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.